HR. 8205Introduced

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Plain-English overview

What this bill does

Reauthorizes through FY2031 and revises federal ALS and rare neurodegenerative disease therapy programs, including research grants, safety reporting, and FDA planning

Key points
  • Require adverse event reporting
  • Direct FDA five year plan
  • Modify NIH grant renewal reviews
  • Extend ALS research grants
Current status

Where it stands

Status
Introduced
Latest action
2026-09-28 — Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
Related context

Topics and policy areas

Select a topic to continue exploring related legislation, members, and committees.

Department of Health and Human ServicesDrug therapyFood and Drug Administration (FDA)Government information and archivesHealthHealth programs administration and fundingInternet, web applications, social mediaMedical research
Discovery signals

About these signals

Methodology

Impact and Momentum are relative discovery aids calculated by Legislation Lemur. They help you scan the congressional record; they are not predictions, endorsements, ideological ratings, or measures of policy importance.

Impact ScoreOverall observed legislative footprint and accumulated activity.
MomentumHow recently active or changing the bill appears in available data.
Full Text (PDF)Amendments
View on Congress.gov